

Saturday June 6th

Time	Sessions in Lund City Hall	All lectures in Lecture hall: Konsertsalen
19.00-19.15	Official opening	
19.15	Welcome lecture Revealing autoimmunity through the genetics of animal models <i>-Rikard Holmdahl, Lund</i>	
20.00	Welcome reception at Lund City Hall	

Sunday June 7th

Time	Sessions in Lund City Hall	
Lecture Hall: Konsertsalen		
09.00	Welcome	
09.05-09.50	Fokko van der Woude lecture <i>Chair: Kerstin Westman, Malmö, Sweden</i> <i>Co-chair: Irmgard Neumann, Vienna, Austria</i>	
	Outcome of AASV-where are we today <i>-Charles Pusey, London, UK</i>	
09.50	Coffee & Exhibition	
Lecture Hall: Konsertsalen		
10.20-12.30	Minisymposium I - Treatment of ANCA-associated small vessel vasculitis <i>Chair: David Jayne, Cambridge, UK</i> <i>Co-chair and organizer: Märten Segelmark</i>	
	10.20-10.40 Current status of experimental therapies for ANCA-Associated vasculitis <i>Peter Merkel, Boston Ma, USA</i>	
	10.40-11.00 Rituximab for ANCA-associated vasculitis (the RAVE-trial) <i>Ulrich Specks, Rochester, Mn, USA and John Stone, Boston, Ma, USA</i>	
	11.00-11.15 A24 Randomised trial of rituximab versus cyclophosphamide for ANCA associated renal vasculitis: RITUXVAS <i>David Jayne, Cambridge, UK</i>	
	11.15-11.25 A3 Characteristics of and rescue-treatment strategies for induction-refractory Wegener's granulomatosis and microscopic polyangiitis patients <i>Raphaële Seror, Paris, France</i>	
	11.25-11.45 A23 Randomised trial of mycophenolate mofetil versus azathioprine for maintenance therapy in ANCA-associated vasculitis (IMPROVE) <i>Thomas Hiemstra, Cambridge, UK</i>	
	11.45-12.00 A22 Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis. A randomised controlled trial. <i>Lorraine Harper, Birmingham, UK</i>	
	12.00-12.30 Panel discussion: Impact of recent data on current standard of care for induction and remission of AAV <i>Jayne/Merkel/Harper/ Specks/Seror/Stone/ Hiemstra/Segelmark</i>	

12.30	Lunch	
	Lecture Hall: Konzertsalen	Lecture Hall: Sessionssalen
13.30-15.00	<p>Minisymposium II Large vessel vasculitis <i>Chair: Maria Cid, Barcelona, Spain</i> <i>Co-chair and organizer: Bo Baslund, Copenhagen, Denmark</i></p> <p>13.30-13.35 Introduction <i>Maria Cid, Barcelona, Spain</i></p> <p>13.35-14.05 Contribution of imaging to the appraisal of extracranial involvement by GCA <i>Wolfgang Schmidt, Weinheim, Germany</i></p> <p>14.05-14.15 B14 Whole body vascular ultrasound examination of 2x22 arteries in patients with suspected GCA <i>Friederike Kesten, Basel, Switzerland</i></p> <p>14.15-14.25 E3 Aortic involvement in patients with newly diagnosed GCA. A prospective study using computed tomography (CT) angiography <i>Sergio Prieto, Barcelona, Spain</i></p> <p>14.25-14.35 B12 Outcome of aortic structural damage after long-term follow-up of patients with GCA <i>Ana Garcia-Martinez, Barcelona, Spain</i></p> <p>14.35-14.45 B6 Intima/media thickening in Takayasu arteritis <i>Rajappa Sivakumar, Chennai, India</i></p> <p>14.45-14.55 B9 Long-term outcome in Takayasu arteritis: vascular procedures performed in active or untreated patients have a poor outcome <i>Muge Bicakcigil, Istanbul, Turkey</i></p>	<p>Minisymposium III Animal models in systemic vasculitis <i>Chair: Peter Herringa, Groningen, The Netherlands</i> <i>Co-chair and organizer: Thomas Hellmark, Lund, Sweden</i></p> <p>13.30-13.40 ANCA-small vessel vasculitides: what have we (not yet) learned from animal models? <i>Peter Herringa, Groningen, The Netherlands</i></p> <p>13.40-14.10 Molecular mimicry and autoimmunity to LAMP-2 in an experimental model of vasculitis <i>Renate Kain, Vienna, Austria</i></p> <p>14.10-14.20 C5 Genetic control of the severity of experimental anti-MPO necrotizing and crescentic glomerulonephritis <i>Hong Xiao, Chapel Hill, NC, USA</i></p> <p>14.20-14.30 C8 PI3Kinase gamma provides a novel therapeutic target in ANCA-induced glomerulonephritis <i>Adrian Schreiber, Berlin, Germany</i></p> <p>14.30-14.40 C9 The role of IL-17 in experimental autoimmune anti-myeloperoxidase induced necrotizing crescentic glomerulonephritis (AIMPOGN) <i>Stephen Holdsworth, Clayton, Australia</i></p> <p>14.40-14.50 C7 p38 MAPK inhibition reduces crescent formation in experimental Anti-MPO-mediated glomerulonephritis <i>Betty S van der Veen, Groningen, The Netherlands</i></p> <p>14.50-15.00 General discussion</p>
15.00	Coffee & Poster session I	

Lecture Hall: Konzertsalen

16.45-17.30	<p><i>Chair: Wladimir Szpirt, Copenhagen, Denmark</i></p> <p>Autoinflammatory syndromes <i>-Ivona Aksentijevich, Bethesda Md, USA</i></p>
-------------	---

Monday June 8th

Time	Sessions in Lund City Hall	
	Lecture Hall: Konsertsalen	Lecture Hall: Sessionsalen
08.30-09.45	<p>Clinical symposium Case reports and diagnostic techniques <i>Principal discussants: Charles Jennette, Chapel Hill, NC, USA (pathologist), Ulrich Specks, Rochester, MN, USA (pulmonologist), Luis Felipe Flores-Suarez, Mexico City, Mexico (rheumatologist)</i></p> <p><i>Co-chairs and organizers: Daina Selga, Lund, Sweden & Wladimir Szpirt, Copenhagen, Denmark</i></p> <p>08.30-08.45 D1 19 years old patient with fulminant Wegener's granulomatosis <i>Jan Sznajd, Krakow, Poland</i></p> <p>08.45-09.00 D42 Wegener's granulomatosis: A fatal relapse after influenza vaccination. A case report <i>Jan Willem Cohen Tervaert, Maastricht, The Netherlands</i></p> <p>09.00-09.15 D31 Recurrent neutropenia, periodic fevers and arthralgias associated with ANCA-positive vasculitis <i>Peter C Grayson, Boston, MA, USA</i></p> <p>09.15-09.30 D8 Angiocentric NK/T-cell lymphoma of the nasopharynx mimicking ENT-limited Wegener's granulomatosis <i>John McLaren, Kirkcaldy, UK</i></p> <p>09.30-09.45 D16 Eosinophilic angiocentric fibrosis: An unusual entity producing saddle nose and nasal septal perforation <i>Patricia Fanlo, Pamplona, Spain</i></p>	<p>Minisymposium IV B-cells and neutrophils in the pathogenesis of AASV <i>Chair: Veronique Witko-Sarsat, Paris</i> <i>Co-chair and organizer: Märten Segelmark, Lund, Sweden</i></p> <p>08.30-09.00 Neutrophils as active participants in cross-talks with other cells of the immune system <i>Marco Cassatella, Verona, Italy</i></p> <p>09.00-9.15 G11 Normal gene silencing mechanisms in mature neutrophils are disrupted in ANCA vasculitis <i>Gloria Preston, Chapel Hill, NC, USA</i></p> <p>09.15-09.25 G3 Calreticulin is a novel PR3 partner that is co-externalized with PR3 during apoptosis but not after degranulation <i>Julie Gabillet, Paris, France</i></p> <p>09.25-09.35 G16 Studies of mechanisms underlying the prolonged neutrophil survival in ANCA-associated systemic vasculitis <i>Mohamed Abdgawad, Lund, Sweden</i></p>
09.45	Coffee and poster session II	
11.00-12.20	<p>11.15-11.28 G7 MPO-positive cell and extracellular MPO in glomeruli of MPO-ANCA associated glomerulonephritis <i>Soko Kawashima, Tokyo, Japan</i></p> <p>11.28-11.41 E5 Endoscopic evaluation of suspected active nasal lesions in Wegener granulomatosis with high histopathological correlation <i>Olga Beltran, Mexico, Mexico</i></p> <p>11.41-11.54 E7 Using the Birmingham vasculitis activity score (BVAS) for diagnosing vasculitis <i>Raashid Luqmani, Oxford, UK</i></p> <p>11.54-12.07 L7 Patient-reported outcome assessment in primary systemic vasculitis with a new instrument provides a unique perspective <i>Karen Herlyn, Lübeck, Germany</i></p> <p>12.07-12.20 L10 Patients with anti-neutrophil cytoplasmic antibody associated vasculitis have an increased risk of cardiovascular disease <i>Matthew Morgan, Birmingham, United Kingdom</i></p>	<p>11.15-11.23 G12 Relative impact of ANCA source and neutrophil donor on the neutrophil response to ANCA stimulation <i>Lorraine Harper, Birmingham, UK</i></p> <p>11.23-11.31 G5 Complement receptor CR3 (Mac-1) is an adaptor for NB1 (CD177)-mediated neutrophil signalling <i>Uwe Jerke, Berlin, Germany</i></p> <p>11.31-11.39 G4 Co-expression of CD177 and membrane proteinase 3 on neutrophils in ANCA-associated vasculitis <i>Nan Hu, Groningen, The Netherlands</i></p> <p>11.39-11.50 Combined discussion on ANCA mediated signalling</p> <p>11.50-12.10 B-cells <i>Donna Bunch, Chapel Hill</i></p> <p>12.10-12.20 F1 B lymphocyte subpopulations in Wegener's granulomatosis and microscopic polyangiitis with special reference to CD25+ expressing B cells <i>Per Eriksson, Linköping, Sweden</i></p>

12.20	Lunch	
	Lecture Hall: Konsertsalen	Lecture Hall: Sessionssalen
13.30-15.00	<p>Minisymposium V Granuloma formation and T-cells <i>Chair: Peter Lamprecht, Bad Bramstedt, Germany</i> <i>Co-chair and organizer: Niels Rasmussen, Copenhagen, Denmark</i></p> <p>13.30-13.50 Clinical aspects of granuloma formation in the ENT tract in WG <i>Petra Ambrosch, Kiel, Germany</i></p> <p>13.50-14.10 M6 On the complex genetics of AASV <i>Jörg Epplen, Bochum, Germany</i></p> <p>14.10-14.30 T-cells in AASV and granuloma formation <i>Cees Kallenberg, Groningen, The Netherlands</i></p> <p>14.30-14.40 I1 A CD8 T cell memory transcription signature predicts prognosis in autoimmune disease <i>Eoin McKinney, Cambridge, UK</i></p> <p>14.40-14.50 I3 Interleukin-15 (IL-15) drives expansion of innate-like CD4 killer T-cells in Wegener's granulomatosis (WG) <i>Mathilde de Menthon, Paris, France</i></p> <p>14.50-15.00 H2 Tissue destruction in localized Wegener's granulomatosis is mediated by fibroblasts after transfer in immunodeficient mice <i>Sebastian Ullrich, Hamburg, Germany</i></p>	<p>Minisymposium VI Vascular biology and vasculitis <i>Chair: Caroline Savage, Birmingham, UK</i> <i>Co-chair and organizer: Sophie Ohlsson, Lund, Sweden</i></p> <p>13.30-13.55 Neutrophil annexin A1 and the control of vascular inflammation: relevance to vasculitis? <i>Mauro Peretti, London, UK</i></p> <p>13.55-14.07 J2 ANCA induced neutrophil microparticles: effect on endothelial cell activation <i>Ying Hong, London, UK</i></p> <p>14.07-14.19 J8 Reduced number of endothelial progenitor cells is predictive of early relapse in antineutrophil cytoplasmic antibody-associated vasculitis <i>Vladimir Tesar, Prague, Czech Republic</i></p> <p>14.19-14.31 J4 Endothelial-derived thrombospondin-1 promotes macrophage recruitment and apoptotic cell clearance <i>Marion Haubitz, Hannover, Germany</i></p> <p>14.31-14.43 J6 Influence of IgG subclass on neutrophil adhesive behaviour and relevance to antineutrophil cytoplasm antibody (ANCA) associated vasculitis <i>Tanya Pankhurst, Birmingham, UK</i></p> <p>14.43-15.00 Symposium summary and discussion, with all speakers in the panel <i>Caroline Savage, Birmingham, UK</i></p>
15.00	Coffee	
	Lecture Hall: Konsertsalen	
15.30-17.00	<p>Pro-Con debate: Etiology of ANCA and AASV</p> <p>Pro 1: Molecular mimicry cause ANCA and subsequently AASV <i>Ronald Falk, Chapel Hill, USA</i></p> <p>Pro 2: Superantigen cause ANCA and AASV <i>Cees Kallenberg, Groningen, The Netherlands</i></p> <p>Con: ANCA is consequence of small vessel vasculitis <i>Philippe Lesavre, Paris, France</i></p>	
19.00	Banquet at Restaurant Glasklart in Malmö	18.30 Buses from Mårtenstorget

Tuesday June 9th

Time	Sessions in Lund City Hall	
Lecture Hall: Konsertsalen		
08.30-09.15	Chair: Kerstin Westman, Malmö, Sweden More is less in type 1 diabetes genome wide association studies - relevance for AASV -Åke Lernmark, Malmö and Seattle:	
09.15	Coffee & Exhibition	
	Lecture Hall: Konsertsalen	Lecture Hall: Sessionssalen
10.00-11.50	Minisymposium VII Epidemiology Chair: Alfred Mahr, Paris, France Co-chair and organizer: Gunnar Sturfelt, Lund, Sweden 10.00-10.05 Short introduction Alfred Mahr, Paris, France 10.05-10.30 Epidemiology of ANCA-vasculitis - 20 years on Richard Watts, Ipswich, UK 10.30-10.40 L5 Improved long-term outcome of 445 Wegener's granulomatosis (WG) patients in a monocentric study over four decades Julia Holle, Lübeck, Germany 10.40-10.50 O3 Bimodal mortality risk in Wegener's granulomatosis Raashid Luqmani, Oxford, UK 10.50-11.00 L11 Predictors of long-term (>= 5 yr) renal survival in 535 patients with ANCA-associated vasculitis Annelies Berden, Leiden, The Netherlands 11.00-11.10 O4 Differentiation between Churg-Strauss-syndrome (CSS) and Hypereosinophilic syndrome (HES). A clinical and multivariate analysis of 213 patients Claudia Metzler, Regensburg, Germany 11.10-11.20 N1 Alpha 1-Antitrypsin deficiency and the risk for Wegener's Granulomatosis Alfred Mahr, Paris, France 11.20-11.50 General discussion	Minisymposium VIII The complement and contact system Chair: Diana Karpman, Lund, Sweden Co-chair and organizer: Kerstin Westman, Malmö, Sweden 10.00-10.05 Introduction Diana Karpman, Lund, Sweden 10.05-10.35 The Complement System in Vasculitis Moh Daha, Leiden, The Netherlands 10.35-10.55 P4 The contact system in vasculitis; neutrophil derived proteinase 3 induces kallikrein-independent release of a novel vasoactive kinin Robin Kahn, Lund, Sweden 11.05-11.15 P2 Complement activation by cytokine-activated neutrophils in relation to ANCA vasculitis Lise Halbwachs-Mecarelli, Paris France 11.15-11.25 P5 The alternative pathway of complement is activated in renal lesions of human MPO- and Pr3-positive ANCA-associated vasculitis Mirjan van Timmeren, Groningen, The Netherlands 11.25-11.35 P3 Neutrophil degranulation and complement release in ANCA-associated vasculitis-an in vitro study Sophie Ohlsson, Lund, Sweden 11.35-11.45 P1 Anti plasminogen and anti-tPA antibodies in patients with ANCA systemic vasculitis inhibit fibrinolysis Peter Hewins, Birmingham, UK
Lecture Hall: Konsertsalen		
11.50-12.00	Summary in Lund	
12.00-14.00	Lunch and busses to Copenhagen	

Time	Sessions at the Serum Institute in Copenhagen
14.00-15.30	<p>Workshop I (Lecture Hall: Foredragssalen) Epitope specificity <i>Chair: Ulrich Specks, Rochester, Mn, USA</i> <i>Co-chair and organizer: Thomas Hellmark, Lund, Sweden</i></p> <p>14.00-14.05 Introduction <i>Ulrich Specks, Rochester, Mn, USA</i></p> <p>14.05-14.25 Functional significance of PR3-ANCA epitopes <i>Dieter Jenne, Martinsried, Germany</i></p> <p>14.25-14.33 Q2 Identification of PR3 epitopes recognized by monoclonal antibodies (moAbs) and PR3-ANCA from patients with Wegener's granulomatosis (WG) <i>Francisco Silva, Rochester, Mn, USA</i></p> <p>14.33-14.41 Q5 Structural basis of the interactions of proteinase 3 with autoantibodies and its NB1 neutrophil membrane receptor <i>Brice Korkmaz, Martinsried, Germany</i></p> <p>14.41-14.49 Q6 Two types of myeloperoxidase-antineutrophil cytoplasmic autoantibodies with a high affinity and a low affinity in small vessel vasculitis <i>Masaharu Yoshida, Tokyo, Japan</i></p> <p>14.49-14.57 Q1 Characterization of MPO-ANCA reactivity in patients with Churg-Strauss syndrome (CSS) <i>Antonella Radice, Milano, Italy</i></p> <p>14.57-15.05 R3 Natural autoantibodies against myeloperoxidase, protease 3 and glomerular basement membrane in normal healthy individuals <i>Zhao Cui, Beijing, China</i></p> <p>15.05-15.25 The significance of epitope specificity in MPO-ANCA associated vasculitis <i>Kazou Suzuki, Chiba, Japan</i></p> <p>15.25-15.30 Concluding discussion</p>
	<p>Workshop II (Lecture Hall: Kantinen) ANCA for diagnosis <i>Chair: Jan Willem Cohen Tervaert, Maastricht, The Netherlands</i> <i>Co-chair and organizer: Jörgen Wieslander, Lund, Sweden</i></p> <p>14.00-14.15 ANCA testing for diagnosing vasculitis <i>Jan Willem Cohen Tervaert, Maastricht, The Netherlands</i></p> <p>14.15-14.30 High quality ANCA testing: long term experience from Bad Bramstedt <i>Elena Csernok, Bad Bramstedt, Germany</i></p> <p>14.30-14.40 T7 Performance of next generation PR3 Elisa's <i>Matthew Hayman, Christchurch, New Zealand</i></p> <p>14.40-14.50 T9 The clinical significance of a positive test for direct MPO ANCA ELISA or capture MPO ANCA Elisa when using international units <i>Mårten Segelmark, Lund, Sweden</i></p> <p>14.50-15.30 Pro and con debate: Time to abandon indirect immunofluorescence when screening for ANCA in systemic vasculitis? Fluorescent green versus a machine: color comes first - <i>Xavier Bossuyt, Leuven, Belgium (pro)</i> Determination of ANCA: comparative analysis of different strategies - <i>Jan Damoiseaux, Maastricht, The Netherlands (con)</i></p>

	<p>Workshop III (Lecture Hall: Seminarrum 1 & 2, Bygning 89) Follow-up of ANCA associated vasculitis <i>Chair: Judy Savige, Melbourne, Australia</i> <i>Co-chair and organizer: Gunnar Houen, Copenhagen, Denmark</i></p> <p>14.00-14.15 ANCA in treated and relapsing disease <i>Judy Savige Melbourne, Australia</i></p> <p>14.15-14.25 U1 Capture ELISA for PR3-ANCA reflects disease activity in NORAM patients <i>Anna Salmela, Helsinki, Finland</i></p> <p>14.25-14.35 U5 Patients have individual and consistent binding patterns to different PR3-ANCA assays <i>Niels Rasmussen, Copenhagen, Denmark</i></p> <p>14.35-14.45 U2 Capture ELISA for PR3-ANCA is superior to detect and predict relapses <i>Daina Selga, Lund, Sweden</i></p> <p>14.45-14.50 Break</p> <p>14.50-14.57 B11 Diagnostic accuracy of eotaxin-3 for Churg–Strauss syndrome <i>Jochen Zwerina, Erlangen, Germany</i></p> <p>14.57-15.04 E2 Angiotensin-2 as a biomarker in ANCA-associated vasculitis <i>Paul Monach, Boston, USA</i></p> <p>15.04-15.11 L8 Osteopontin as a marker and mediator of disease activity in ANCA-associated vasculitis <i>Johan Lorenzen, Hannover, Germany</i></p> <p>15.11-15.30 Panel discussion: Development of guidelines for ANCA testing in treated disease and comparison with other markers <i>Judy Savige and panel of presenters</i></p>
15.30	Coffee and walk to final workshop session
16.00-17.00	<p>Plenary session (Lecture Hall: Gymnastiksalen) Hot spots for further research and proposals for guidelines for the use of ANCA for diagnosis and follow-up <i>Chair: Niels Rasmussen, Copenhagen, Denmark</i> <i>Co-chair: Allan Wiik, Copenhagen, Denmark</i></p>
19.00	Farewell buffet at Tivoli, Copenhagen